A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers by Addo, S et al.
A phase I trial to assess the pharmacology of the new oestrogen
receptor antagonist fulvestrant on the endometrium in healthy
postmenopausal volunteers
S Addo
1, RA Yates
2 and A Laight*
,2
1LCG Bioscience, Bourn Hall Clinic, Bourn, Cambridge, UK;
2AstraZeneca Pharmaceuticals, Alderley Park, Macclesﬁeld, Cheshire SK10 4TG, UK
While tamoxifen use is associated with clear beneﬁts in the treatment of hormone-sensitive breast cancer, it also exhibits
partial oestrogen agonist activity that is associated with adverse events, including endometrial cancer. Fulvestrant (‘Faslodex’) is
a new oestrogen receptor antagonist that downregulates the oestrogen receptor and has no known agonist effect. This single-
centre, double-blind, randomised, parallel-group trial was conducted to determine the direct effects of fulvestrant on the
female endometrium when given alone and in combination with the oestrogen, ethinyloestradiol. Following a 14-day, pretrial
screening period, 30 eligible postmenopausal volunteers were randomised to receive fulvestrant 250 mg, fulvestrant 125 mg
or matched placebo administered as a single intramuscular injection. Two weeks postinjection, volunteers received 2-weeks
concurrent exposure to ethinyloestradiol 20 mg day
71. Endometrial thickness was measured before and after the 14-day
screening period with further measurements predose (to conﬁrm a return to baseline) and on days 14, 28 and 42 post-
treatment with fulvestrant. Pharmacokinetic and safety assessments were performed throughout the trial. Fulvestrant at a dose
of 250 mg signiﬁcantly (P=0.0001) inhibited the oestrogen-stimulated thickening of the endometrium compared with placebo.
Neither the 125 mg nor 250 mg doses of fulvestrant demonstrated oestrogenic effects on the endometrium over the initial
14-day assessment period. Fulvestrant was well tolerated and reduced the incidence of ethinyloestradiol-related side effects.
At the same dose level that is being evaluated in clinical trials of postmenopausal women with advanced breast cancer,
fulvestrant (250 mg) is an antioestrogen with no evidence of agonist activity in the endometrium of healthy postmenopausal
women.
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Non-steroidal antioestrogens such as tamoxifen (‘Nolvadex’) have
revolutionised the treatment of breast cancer over the last 30 years.
In particular, tamoxifen has become established as the ‘gold stan-
dard’ for the treatment of all stages of breast cancer (Early
Breast Cancer Triallists Collaborative Group [EBCTCG], 1992;
1998) and has also been shown to have a role in the prevention
of primary and contralateral breast cancer (Fisher et al, 1998;
reviewed by Chlebowski et al, 1999; Narod et al, 2000; King et
al, 2001). Although the oestrogenic activity of long-term tamoxifen
therapy helps to maintain bone density, (Love et al, 1992) and
reduce circulating low-density lipoprotein cholesterol (Love et al,
1990; Bilmoria et al, 1996), it is also associated with partial oestro-
gen agonist activity linked with endometrial proliferation and an
increased risk of endometrial cancer (Fisher et al, 1994; 1998; Berg-
man et al, 2000). Compared to non-tamoxifen treated women, the
endometrial cancer associated with long-term tamoxifen use has a
worse prognosis, probably due to it exhibiting a less favourable
histology and higher stage (Bergman et al, 2000). These adverse
events have therefore raised concerns about the long-term use
of tamoxifen. More recently, drugs that inhibit aromatase, and
thereby block the conversion of androgen to oestrogen in postme-
nopausal women, have become valuable options for the treatment
of advanced breast cancer.
In contrast to tamoxifen, fulvestrant (‘Faslodex’) is a new oestro-
gen receptor (ER) antagonist that downregulates cellular levels of
the ER and has no known agonist effects. In preclinical studies,
fulvestrant shows no oestrogen-like activity and completely ablates
the activity of endogenous oestrogens (Wakeling et al, 1991). More-
over, magnetic resonance imaging of the uterus in ovarectomised
monkeys also suggests that fulvestrant is an effective antioestrogen
(Dukes et al, 1992, 1993). The data surrounding the clinical poten-
tial of fulvestrant in postmenopausal patients with breast cancer
have been encouraging (Defriend et al, 1994; Howell et al, 1996,
2002; Osborne et al, 2002). In this group of patients, fulvestrant
inhibits tumour cell proliferation associated with a profound
decrease in immunocytochemically detectable ER protein (Defriend
et al, 1994; Robertson et al, 2001). One small phase II trial, invol-
ving 19 postmenopausal patients with tamoxifen refractory
disease, suggested that fulvestrant might have fewer side effects in
terms of menopausal symptoms than tamoxifen, with no negative
effects being observed on the liver, brain or genital tract (Howell
et al, 1996). The pharmacokinetic data associated with these studies
in breast cancer patients showed that monthly intramuscular (i.m.)
injections of fulvestrant 250 mg maintained detectable plasma levels
of drug over a period of 28 days and resulted in a marked reduction
in levels of ER protein (Howell et al, 1996; Robertson et al, 2000,
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tase inhibitor anastrozole in terms of time to progression, and
secondary endpoints including objective response and clinical bene-
ﬁt, in two randomised phase III trials in postmenopausal women
with locally advanced or metastatic breast cancer who had
progressed following prior endocrine therapy for either advanced
or early breast cancer (Howell et al, 2002; Osborne et al, 2002).
Rates of adverse events (AEs) were similar in both arms of the
two trials.
There has been no suggestion to date that fulvestrant produces
ovarian or endometrial stimulation in postmenopausal women
(Defriend et al, 1994; Howell et al, 1996) and the lack of agonist
activity associated with fulvestrant suggests an improved efﬁcacy
and tolerability proﬁle relative to tamoxifen. The present trial
was conducted in healthy postmenopausal volunteers to speciﬁcally
assess the pharmacological effects of fulvestrant on the postmeno-
pausal endometrium.
VOLUNTEERS AND METHODS
Volunteers
This was a double-blind, randomised, parallel-group, single-centre
trial in healthy, postmenopausal volunteers (Figure 1). The proto-
col was approved by the local ethics committee prior to volunteer
recruitment. All volunteers provided signed informed consent
before undergoing a routine pretrial medical examination, includ-
ing ultrasound assessment to measure endometrial thickness.
Following the pretrial medical examination, volunteers were
eligible to enter the screening period of the trial if they:
(1) were aged between 45 and 60 years;
(2) were postmenopausal (deﬁned as not having experienced
menstruation for more than 1 year and having serum luteinising
hormone (LH), follicle-stimulating hormone (FSH) and
oestradiol levels in the postmenopausal range);
(3) had a normal clinical assessment including medical history and
resting ECG;
(4) had an endometrial thickness at baseline of 44 mm, and had at
least one ovary and a normal uterus;
(5) weighed within 20% of their desired bodyweight;
(6) had undergone a normal cervical smear within the last 5 years
and had a normal mammogram within the last 3 years.
Individuals were excluded if they had a history of:
(1) prior HRT;
(2) oestrogen-dependent conditions including breast cancer;
(3) disease affecting bone or steroid metabolism;
(4) any conditions known to increase the risk of thromboembolic
events;
(5) use of drugs known to affect sex hormone status or steroid
metabolism;
(6) gastrointestinal, hepatic or renal disease that might interfere
with absorption, metabolism and excretion of drugs.
Screening
Eligible volunteers entered the screening period, during which time
they received oral ethinyloestradiol 20 mg day
-1 (two610 mg
tablets) at the same time each day for a period of 14 days. Only
those volunteers with an endometrial response, deﬁned as an endo-
metrial thickness of 58 mm after oestrogen treatment, were
allowed to continue on the trial after a ‘washout period’ of 2–6
weeks following the ﬁrst course of oestrogen. Volunteers were
excluded from the randomised phase of the trial if their endome-
trial thickness did not return to baseline after the ‘washout period’.
Randomisation
Eligible volunteers were randomised in a 1:1:1 ratio to receive
fulvestrant 250 mg, fulvestrant 125 mg or matched placebo. Rando-
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Fulvestrant (250 mg)
Figure 1 Study design. N.B. Fulvestrant administered as a single intramuscular injection, which provided continuous exposure over at least a 28-day
period.
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vidual was determined by a random scheme prepared by the
Biostatistics Group at AstraZeneca. All treatments were administered
into the buttock as a single i.m. injection, which provided continu-
ous exposure to fulvestrant over at least a 28-day period. Two weeks
after administration of the randomised trial medication, all volun-
teers received a further 2-weeks exposure to ethinyloestradiol
20 mg day
71. Hence, the ﬁrst 14-day exposure to fulvestrant (treat-
ment period 1) assessed the effects of fulvestrant alone, while the
subsequent 14-day period of exposure (treatment period 2) assessed
the combination of fulvestrant 125 or 250 mg plus ethinyloestradiol,
and ethinyloestradiol alone. No concomitant medication, other than
simple analgesia, was allowed from 72 h before screening, day 1,
until completion of the post-trial medical examination, without
the prior consent of the investigator.
Endometrial thickness
The primary endpoint of this trial was endometrial thickness. All
volunteers underwent an ultrasound scan of the endometrium to
determine endometrial thickness at the pretrial medical examination
and after receiving 14 days of ethinyloestradiol (20 mg day
71)o n
day 14 of the screening period. Volunteers whose endometrium
had not returned to baseline thickness after the screening period
were not randomised. However, a further ultrasound could be
performed after a longer ‘washout’ if the investigator considered it
to be appropriate. Subsequent ultrasound scans were performed
on days 14 (end of period 1), 28 (end of period 2) and 42 post-treat-
ment with fulvestrant or placebo. The endometrial measurement,
deﬁned as the combined thickness of the two endometrial layers
lying side by side, was performed through the thickest area of the
endometrium. The measurement was performed in the longitudinal
plane and then the transverse plane at the same location. The
measurement markers were placed at the boundary between the
myometrium and endometrium and the measurement recorded.
Pharmacokinetic assessments
Venous blood was taken prior to dosing with either fulvestrant
(125 mg or 250 mg) or placebo (day 1), 2 h after dosing (day 1)
and on trial days 3, 7, 11, 14, 21 and 28. Determinations of maxi-
mum plasma concentration (Cmax), area under plasma
concentration-time curve from zero to day 27 (AUC(0–27)) and
time to maximum plasma concentration (tmax) were made. The
analyses were based on a validated high-performance liquid chro-
matography method with tandem mass spectrometry (Analytico
Medinet BV, The Netherlands) (Data on ﬁle, AstraZeneca), the
results of which have been presented previously (Robertson,
2000; Robertson et al, 2000).
Safety
The safety assessments made in this trial were AEs, clinical chem-
istry, haematology and urinalysis. The AEs were recorded by the
investigator and categorised according to COding Symbols for
Thesaurus of Adverse Reaction Terms (COSTART) classiﬁcation
and body systems. An AE was deﬁned as the development of any
medical condition or deterioration of a pre-existing condition.
The medical condition did not need to have had a causal relation-
ship with exposure to the trial treatments and could be symptoms
(e.g. nausea and chest pain) or abnormal results on investigation
(e.g. blood tests, scans or ECG).
Statistics
The size of the study was based upon the primary trial endpoint,
endometrial thickness. Using data from previous trials, it was
considered necessary for the trial to be able to detect a difference
in endometrial thickness of 8.0 mm between the fulvestrant and
placebo treated groups. Based upon an estimation of between-
volunteer variability, it was calculated that nine volunteers per
group would be required to allow an 85% chance of detecting
an 8.0 mm difference in endometrial thickness between fulvestrant
and placebo treated groups. Ten volunteers per group were there-
fore considered satisfactory to provide sufﬁcient power to
determine signiﬁcant changes in endometrial thickness, while at
the same time allowing for the possible withdrawal of one subject
per group. As a result, a total of 30 volunteers were required.
Only the data obtained from the measurement of endometrial
thickness were subject to formal statistical analysis (t-test). Non-
compartmental pharmacokinetic analysis was performed on the
plasma concentration-time data. Cmax and tmax were determined
from the fulvestrant plasma concentration-time proﬁles, and
AUC(0–27) was calculated using the linear trapezoidal rule. The
data were presented using the following summary statistics:
geometric mean (gmean), coefﬁcient of variance (CV), gmean stan-
dard deviation (s.d.), arithmetic mean (calculated using
untransformed data) and s.d. (calculated using untransformed
data) depending on the parameter. tmax was presented as median,
minimum, maximum.
RESULTS
Volunteer demographics
A total of 30 healthy, postmenopausal, female volunteers were
recruited into the trial and received one course of 20 mg day
71
ethinyloestradiol for 14 days during screening. All 30 volunteers
had a positive response to the administered oestrogen and were
subsequently randomised as follows: 10 patients to receive fulves-
trant 125 mg, 10 patients to receive fulvestrant 250 mg and 10
patients to receive placebo. The three treatment groups were
well-matched for age, with the mean age (range) for the placebo,
fulvestrant 125 mg and fulvestrant 250 mg treated patients being
56.8 years (48–64), 55.0 years (49–64) and 58.9 years (56–63),
respectively. Similarly, mean weight and height were comparable
between the three groups, with a mean weight (range) of 65.8 kg
(54–76), 62.7 kg (48–76) and 61.1 kg (21–71), and a mean
height (range) of 162.7 cm (153–169), 163.1 cm (153–171) and
161.1 cm (150–168), for the placebo, fulvestrant 125 mg and
fulvestrant 250 mg treated patients, respectively.
There were no withdrawals or protocol violations during the
trial. However, one patient was excluded from statistical analysis
due to a protocol deviation. This patient took only one ethinyloes-
tradiol tablet per day during the ethinyloestradiol treatment phase.
Ten other volunteers had protocol deviations that did not lead to
exclusion from statistical analysis. All 30 volunteers were included
in the safety analyses.
Endometrial thickness
At screening, all 30 volunteers had a normal postmenopausal base-
line endometrial thickness of 44 mm and responded to the
screening oestrogen challenge with an increase in endometrial
thickness to 58 mm. Endometrial thickness after 14 days of
20 mg day
-1 ethinyloestradiol varied between 8 and 12 mm except
for one volunteer whose endometrial thickness had increased to
20 mm.
In all groups, the baseline value on day 1 was slightly elevated
compared with the screening value, suggesting that the endometrial
thickness after 14 days of oestrogen stimulation had not completely
returned to preoestrogen levels, however the differences appeared
to be within the level of variability observed for endometrial thick-
ness at these time points. For all volunteers the endometrial
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days after administration of i.m. fulvestrant, at a dose of either
125 mg or 250 mg, the mean endometrial thickness in each group
was not clinically different from the screening value for that group,
with no clinically signiﬁcant differences between the groups
(Table 1).
Following the 14-day treatment period 2, during which time
ethinyloestradiol was administered in addition to fulvestrant
(125 mg or 250 mg) and placebo, the mean endometrial thickness
for the three groups was 7.70 mm for fulvestrant 125 mg plus ethi-
nyloestradiol, 4.20 mm for fulvestrant 250 mg plus
ethinyloestradiol, and 11.22 mm for placebo plus ethinyloestradiol,
respectively (Table 1). There was a statistically signiﬁcant difference
between the fulvestrant 250 mg-treated group and the placebo-
treated group for the change in mean endometrial thickness
between day 1 and day 28 (P=0.0001) (Table 1). There was no
statistically signiﬁcant difference between the fulvestrant 125 mg
group and the placebo group (P=0.0742) (Table 2). The mean
endometrial thickness from pretrial to 42 days post-treatment with
placebo or fulvestrant is plotted in Figure 2.
Pharmacokinetics
A summary of the pharmacokinetic parameters is presented in
Table 2. The gmean peak plasma concentrations of fulvestrant rose
to 4.55 and 11.38 ng ml
-1 approximately 6 days after i.m. injection
of 125 mg and 250 mg fulvestrant, respectively (Figure 3). By trial
day 28, the plasma concentrations had declined approximately
four-fold (Table 2). Exposure following the 250 mg dose of fulves-
trant (AUC0–27) was approximately 2.5 times greater than that
derived from the 125 mg dose. Higher plasma concentrations of
fulvestrant (assessed on day 28) were associated with greater reduc-
tions in endometrial thickness.
Safety
There were no serious AEs or events leading to volunteer withdra-
wal during this trial. Twenty-six volunteers reported a total of 77
AEs during the screening phase. During the ﬁrst 14 days of the
trial, 16 volunteers reported 28 AEs across all treatment groups,
and during days 15 to 28, 22 volunteers reported 57 AEs across
all treatment groups. Overall, the commonly reported AEs (i.e.
those occurring in 520% volunteers) were headache, leucorrhoea,
breast pain and abdominal pain (Table 3).
The majority of AEs (105 out of a total of 162) occurred in
volunteers receiving ethinyloestradiol alone either in the screening
phase or in combination with placebo. The number of AEs
reported during days 15 to 28 of treatment period 2, in the group
receiving fulvestrant 250 mg plus ethinyloestradiol was less than
half the number reported over the same time period in the group
who received ethinyloestradiol plus placebo. Fulvestrant appeared
to reduce the incidence of some of the ethinyloestradiol-induced
AEs such as breast pain. Most of the AEs reported by volunteers
receiving fulvestrant were considered to be treatment related and
consisted of ﬂushing, headache and injection-site reaction. There
were no dose-related trends in the reporting of AEs.
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Figure 2 Mean endometrial thickness from premedical examination to
trial day 42. Abbreviations: Pre=premedical examination; D14=after 14
days of ethinyloestradiol treatment; T1=treatment day 1 immediately be-
fore patients received either placebo or fulvestrant (125 mg or 250 mg);
T14=day 14 when volunteers received their second challenge with ethiny-
loestradiol; T28=day 28 post-treatment at the end of the second ethiny-
loestradiol challenge; T42=day 42 post-treatment.
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Figure 3 Geometric mean (s.d.) plasma concentrations of fulvestrant.
Day 1 concentration was taken 2 h after dosing; day 14 concentration
was taken pre-inﬂation of cuff.
Table 1 Endometrial thickness on days 1, 14 and 28
Endometrial Fulvestrant Fulvestrant
thickness 125 mg 250 mg Placebo
(mm) (n=10) (n=10) (n=9)
Day 1 (pre-dose)
Mean 3.00 2.70 3.11
s.d. 0.82 0.82 0.60
Day 14
a
Mean 2.30 1.90 2.44
s.d. 0.48 0.57 0.53
Day 28
b
Mean 7.70 4.20 11.22
s.d. 5.12 1.48 3.19
Mean change in endometrial 4.7 1.5 8.11
thickness (mm) (Day 1–day 28)
Estimated treatment effect
c 73.41 76.61 –
P-value
d 0.0742 0.0001
aFourteen days after the administration of trial medication;
bAfter the second course
of ethinyloestradiol 20 mg day
71 for 14 days;
cTreatment effect is difference between
fulvestrant mean endometrial thickness and placebo;
dChange in mean endometrial
thickness vs placebo. Abbreviations: n=number of volunteers; s.d.=standard deviation.
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A reduction in oestrogenic stimuli forms the basis of treatment for
many benign and malignant diseases of the breast and reproductive
tract. This study was conducted to examine the effect of fulves-
trant, a new ER antagonist, both alone and in combination with
ethinyloestradiol, on the endometrium of healthy postmenopausal
women.
Compared with volunteers who received unopposed ethinyloes-
tradiol, those women who received the combination of fulvestrant
and ethinyloestradiol had reduced endometrial thickening, demon-
strating an antioestrogenic effect of fulvestrant on normal
postmenopausal endometrium. The difference in endometrial
thickening was clinically and statistically signiﬁcant in volunteers
who received the 250 mg dose of fulvestrant, the dose evaluated
in the breast cancer setting. Although endometrial thickness was
reduced in volunteers receiving fulvestrant 125 mg compared with
the placebo group, the mean difference was smaller and failed to
reach statistical signiﬁcance, suggesting the response to fulvestrant
was dose related.
Fulvestrant also demonstrated no oestrogen agonist effect on the
endometrium during the short-term (14 day) period of administra-
tion. There were no clinically signiﬁcant differences in endometrial
thickness between the fulvestrant and placebo groups.
Overall, fulvestrant at both doses, either alone or in combination
with ethinyloestradiol, was well tolerated. Most of the AEs were
associated with ethinyloestradiol dosing or were considered not
to be drug related. Fulvestrant appeared to reduce the number of
ethinyloestradiol-related events providing further evidence for the
antioestrogenic effects of this agent. The pharmacokinetic data
were consistent with previous studies in patients with breast cancer
(Howell et al, 1996; Robertson et al, 2000).
In conclusion, the results of this trial demonstrate an antioestro-
genic effect of fulvestrant at doses of 125 and 250 mg on the
endometrium. In addition, in the absence of oestrogen, fulvestrant
demonstrated no oestrogen agonist effects during the 14-day peri-
od of administration. These data conﬁrm that fulvestrant 250 mg,
a dose known to be active in breast cancer therapy, is a well-toler-
ated oestrogen antagonist that is devoid of agonist activity on the
endometrium in healthy, postmenopausal women.
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